Daniel Ebner
Professor - Principal Investigator in Cellular High Throughput Screening
Daniel Ebner is an Associate Professor and Principal Investigator at the University of Oxford and heads the TDI High Throughput Cellular Screening Facility and the Oxford CRISPR/Cas9 Screening Facility at the Target Discovery Institute (TDI), Centre for Medicines Discovery, Nuffield Department of Medicine. Daniel’s main academic research, through a five year £7M CRUK funded grant in collaboration with researchers from the University of Edinburgh and MIT, is focused on identifying and advancing novel combinatorial therapeutics for the treatment of glioblastoma. As head of the cellular screening facility, Daniel has worked with academic and industrial collaborators to complete >150 research projects and has published >70 peer-reviewed papers in the past 5 years in high impact journals such as the Lancet, New England Journal of Medicine, Nature and Journal of the American Medical Association across a broad range of pathologies including on neurodegeneration, inflammation, autophagy, large-scale iPSC CRISPR/Cas9 screening methods, and novel more physiologically relevant screening models. Previous to his academic career at the University of Oxford, Daniel has worked for >10 years in the biotechnology and pharmaceutical industry.
Recent publications
-
The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity
Preprint
Hmedat ANA. et al, (2024)
-
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Journal article
Bleloch JS. et al, (2024), Cancer Med, 13
-
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Journal article
Kent D. et al, (2024), Hepatology
-
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Journal article
Pouwels KB. et al, (2024), Nat Commun, 15
-
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Journal article
Baugh R. et al, (2024), J Immunother Cancer, 12